Ovid Therapeutics Ownership
| OVID Stock | USD 0.66 0 0.45% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 71.2 M | Current Value 71 M | Avarage Shares Outstanding 48.8 M | Quarterly Volatility 21.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ovid |
Ovid Stock Ownership Analysis
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.65. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ovid Therapeutics recorded a loss per share of 0.46. The entity had not issued any dividends in recent years. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To find out more about Ovid Therapeutics contact Zoology Dphil at 646 661 7661 or learn more at https://www.ovidrx.com.Besides selling stocks to institutional investors, Ovid Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ovid Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ovid Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ovid Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 16.0% of Ovid Therapeutics are currently held by insiders. Unlike Ovid Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ovid Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ovid Therapeutics' insider trades
Ovid Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ovid Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ovid Therapeutics backward and forwards among themselves. Ovid Therapeutics' institutional investor refers to the entity that pools money to purchase Ovid Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tls Advisors Llc | 2024-09-30 | 771.5 K | Wells Fargo & Co | 2024-09-30 | 735.2 K | Prosight Management, Lp | 2024-09-30 | 729.2 K | Ubs O'connor Llc | 2024-09-30 | 628.3 K | Northern Trust Corp | 2024-09-30 | 480.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 309.5 K | Gsa Capital Partners Llp | 2024-09-30 | 260.5 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 220.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 165.8 K | Rubric Capital Management Lp | 2024-09-30 | 5.3 M | Blackrock Inc | 2024-09-30 | 4.3 M |
Ovid Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ovid Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ovid Therapeutics Outstanding Bonds
Ovid Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ovid Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ovid bonds can be classified according to their maturity, which is the date when Ovid Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share | Quarterly Revenue Growth 0.587 | Return On Assets | Return On Equity |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.